CNBX (CNBX Pharmaceuticals) Total Assets: $0.01 Mil (As of May. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is CNBX Pharmaceuticals Total Assets?

CNBX Pharmaceuticals CNBX +33.33% Total Assets is $0.01 Mil as of May. 2026. The stock has 3 warning signs investors should review.

CNBX Pharmaceuticals's Total Assets for the quarter that ended in May. 2026 was $0.01 Mil.

During the past 12 months, CNBX Pharmaceuticals's average Total Assets Growth Rate was -20.00% per year. During the past 3 years, the average Total Assets Growth Rate was -83.70% per year. During the past 5 years, the average Total Assets Growth Rate was -75.30% per year. During the past 10 years, the average Total Assets Growth Rate was -3.90% per year.

During the past 13 years, CNBX Pharmaceuticals's highest 3-Year average Total Assets Growth Rate was 1226.10%. The lowest was -85.70%. And the median was 36.45%.

Total Assets is connected with ROA %. CNBX Pharmaceuticals's annualized ROA % for the quarter that ended in May. 2026 was -4,400.00%. Total Assets is also linked to Revenue through Asset Turnover. CNBX Pharmaceuticals's Asset Turnover for the quarter that ended in May. 2026 was 0.00.

CNBX Pharmaceuticals  (OTCPK:CNBX) Total Assets Explanation

Total Assets is connected with ROA %.

CNBX Pharmaceuticals's annualized ROA % for the quarter that ended in May. 2026 is

ROA %=Net Income (Q: May. 2026 )/( (Total Assets (Q: Feb. 2026 )+Total Assets (Q: May. 2026 ))/ count )
=-0.616/( (0.015+0.013)/ 2 )
=-0.616/0.014
=-4,400.00 %

Note: The Net Income data used here is four times the quarterly (May. 2026) data.

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Total Assets is linked to total revenue through Asset Turnover.

CNBX Pharmaceuticals's Asset Turnover for the quarter that ended in May. 2026 is

Asset Turnover
=Revenue (Q: May. 2026 )/( (Total Assets (Q: Feb. 2026 )+Total Assets (Q: May. 2026 ))/ count )
=0/( (0.015+0.013)/ 2 )
=0/0.014
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.

CNBX Pharmaceuticals Total Assets Related Terms

CNBX Pharmaceuticals Total Assets Historical Data

* Premium members only.

The historical data trend for CNBX Pharmaceuticals's Total Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

CNBX Pharmaceuticals Total Assets Chart

CNBX Pharmaceuticals Annual Data
Trend Aug16 Aug17 Aug18 Aug19 Aug20 Aug21 Aug22 Aug23 Aug24 Aug25
Total Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.08 0.81 0.50 0.03 0.02

CNBX Pharmaceuticals Quarterly Data
Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24 May24 Aug24 Nov24 Feb25 May25 Aug25 Nov25 Feb26 May26
Total Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.02 0.02 0.01 0.02 0.01

CNBX Pharmaceuticals Total Assets Calculation

Total Assets are all the assets a company owns.

From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.

CNBX Pharmaceuticals's Total Assets for the fiscal year that ended in Aug. 2025 is calculated as

Total Assets=Total Equity (A: Aug. 2025 )+Total Liabilities (A: Aug. 2025 )
=-2.496+2.515
=0.02

CNBX Pharmaceuticals's Total Assets for the quarter that ended in May. 2026 is calculated as

Total Assets=Total Equity (Q: May. 2026 )+Total Liabilities (Q: May. 2026 )
=-2.66+2.673
=0.01

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Assets →
What does a Total Assets of $0.01 Mil mean?
CNBX Pharmaceuticals (CNBX) has a Total Assets of $0.01 Mil as of May. 2026. The total amount of assets as recorded on a company's balance sheet. View historical data on CNBX Pharmaceuticals and its competitors.
Is CNBX Pharmaceuticals' Total Assets too high?
CNBX Pharmaceuticals' current Total Assets is $0.01 Mil.
How does CNBX Pharmaceuticals' Total Assets compare to SIGY and LIPO?
CNBX Pharmaceuticals' Total Assets of $0.01 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Assets for a Biotechnology company?
A good Total Assets depends on the Biotechnology industry context. However, Total Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Assets mean?
A high Total Assets can signal that a stock is expensive relative to its fundamentals. The total amount of assets as recorded on a company's balance sheet. View historical data on CNBX Pharmaceuticals and its competitors. CNBX Pharmaceuticals's current Total Assets is $0.01 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CNBX Pharmaceuticals stock overvalued right now?
CNBX Pharmaceuticals (CNBX) has a current Total Assets of $0.01 Mil. The current Total Assets is $0.01 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Assets calculated?
Total Assets is calculated from a company's financial statements. For CNBX Pharmaceuticals (CNBX), the current Total Assets is $0.01 Mil as of May. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

CNBX Pharmaceuticals Business Description

Address No. 3 Bethesda Metro Center, Suite 700, Bethesda, MD, USA, 20814
CNBX Pharmaceuticals Inc is a clinical-stage biotechnology company. It develops pharmaceuticals focusing on cancer research utilizing HTS technology and personalized bioinformatics tools. The company's main focus is the development of cannabinoid therapies and other technologies for the treatment of cancer, mainly cancers of the gastrointestinal tract, skin, breast, and prostate. The firm's main product is the Cannabics SR, an oral capsule developed for the treatment of patients with cancer and cancer anorexia cachexia syndrome (CACS). It also has an anti-neoplastic drug candidate under development for Colorectal Cancer (CRC) named RCC-33.